Hillsdale Investment Management Inc. acquired a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 150,200 shares of the biopharmaceutical company's stock, valued at approximately $4,521,000. Hillsdale Investment Management Inc. owned 0.10% of TG Therapeutics at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently modified their holdings of the company. State Street Corp boosted its position in TG Therapeutics by 35.8% during the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company's stock worth $212,712,000 after acquiring an additional 2,398,015 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in TG Therapeutics by 1,549.4% during the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock worth $18,061,000 after purchasing an additional 725,371 shares during the last quarter. Raymond James Financial Inc. acquired a new position in TG Therapeutics during the fourth quarter worth $14,508,000. Braun Stacey Associates Inc. bought a new position in TG Therapeutics in the fourth quarter valued at $13,328,000. Finally, Castellan Group acquired a new stake in TG Therapeutics in the 4th quarter valued at $8,539,000. 58.58% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
TGTX has been the subject of several analyst reports. StockNews.com raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and set a $55.00 target price on shares of TG Therapeutics in a report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $40.67.
View Our Latest Stock Analysis on TGTX
TG Therapeutics Price Performance
Shares of TGTX traded down $2.01 during mid-day trading on Wednesday, reaching $40.79. The company had a trading volume of 2,324,318 shares, compared to its average volume of 2,982,487. The company has a market capitalization of $6.41 billion, a price-to-earnings ratio of -407.86 and a beta of 2.30. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The company's 50 day simple moving average is $33.95 and its 200 day simple moving average is $30.11. TG Therapeutics, Inc. has a 1-year low of $12.93 and a 1-year high of $43.32.
TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. The firm had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. Analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.
Insider Activity at TG Therapeutics
In related news, CFO Sean A. Power sold 11,337 shares of the stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $30.29, for a total transaction of $343,397.73. Following the transaction, the chief financial officer now directly owns 670,632 shares of the company's stock, valued at $20,313,443.28. This represents a 1.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.50% of the stock is currently owned by company insiders.
TG Therapeutics Profile
(
Free Report)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Featured Articles
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
